DrugPatentWatch Database Preview

Details for Patent: 9,597,398

« Back to Dashboard

Which drugs does patent 9,597,398 protect, and when does it expire?

Patent 9,597,398 protects BENDEKA and is included in one NDA.

This patent has thirty-two patent family members in fifteen countries.

Summary for Patent: 9,597,398

Title:	Formulations of bendamustine
Abstract:	Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed. The methods conveniently allow shorter administration time without the active ingredient coming out of solution as compared to presently available formulations.
Inventor(s):	Sundaram; Srikanth (Somerset, NJ)
Assignee:	EAGLE PHARMACEUTICALS, INC. (Woodcliff Lake, NJ)
Application Number:	15/008,819
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,597,398
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 9,597,398

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Eagle Pharms	BENDEKA	bendamustine hydrochloride	SOLUTION;IV (INFUSION)	208194-001	Dec 7, 2015		RX	Yes	Yes						FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

International Family Members for US Patent 9,597,398

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2867295
Canada	2867343
China	104271135